Elixir Medical’s DeSyne stent tops Medtronic’s Endeavor after 5 years

Elixir Medical‘s novolimus-eluting stent, DeSyne, outperformed Medtronic‘s (NYSE:MDT) zotarolimus-eluting stent, Endeavor, according to long-term data from Elixir’s Excella II trial.

The study enrolled 210 patients with 2 or more de novo lesions in 2 different epicardial vessels. Researchers randomly assigned patients in a 2:1 ratio to the novolimus-eluting stent or the zotarolimus-eluting stent.

Get the full story at our sister site, Drug Delivery Business News.

The post Elixir Medical’s DeSyne stent tops Medtronic’s Endeavor after 5 years appeared first on MassDevice.